No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes
- DOI
- 10.1111/cts.70431
- Published
- 2025-12
- Container
- Clinical and Translational Science
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1111/cts.70431,
title = {No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes},
author = {Ashley L. Lennox and Fei Huang and Mario González‐Sales and Ying Wan and Libo Sun and Tymara Berry and Faye Feller and Peter N. Morcos},
year = {2025},
journal = {Clinical and Translational Science},
doi = {10.1111/cts.70431},
url = {https://doi.org/10.1111/cts.70431}
}RIS
TY - JOUR TI - No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes AU - Ashley L. Lennox AU - Fei Huang AU - Mario González‐Sales AU - Ying Wan AU - Libo Sun AU - Tymara Berry AU - Faye Feller AU - Peter N. Morcos PY - 2025 JO - Clinical and Translational Science DO - 10.1111/cts.70431 UR - https://doi.org/10.1111/cts.70431 ER -
APA
Lennox, A. L., Huang, F., González‐Sales, M., Wan, Y., Sun, L., Berry, T., Feller, F., & Morcos, P. N. (2025). No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes. Clinical and Translational Science. https://doi.org/10.1111/cts.70431
Source records
- crossref · retrieved 2026-09-26T20:43:46.191Z